Current issue
Archive
Online first
About the Journal
Editorial Office
Editorial Board
Publisher
Editorial Policies
Ethical standards and procedures
Abstracting and indexing
Reviewers
Honorary Reviewers
Subscription
Contact
Most read articles
Instructions for authors
Article processing charge (APC)
Books and Events
Books
Events
REVIEW PAPER
Lipid profiles in rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs
Submission date: 2013-10-14
Acceptance date: 2014-02-26
Online publication date: 2014-06-04
Publication date: 2014-04-30
Reumatologia 2014;52(2):120-128
KEYWORDS
TOPICS
ABSTRACT
Cardiovascular events are the main cause of the increased risk of death in patients with rheumatoid arthritis (RA). Death rates associated with cardiovascular diseases in RA are 50% higher in comparison with the general population. In the last decade several new technologies and new strategy in the treatment of RA were introduced but the risk of cardiovascular incidents remained unchanged. Various alterations of the lipid profile, observed in RA patients during the treatment with disease modifying antirheumatic drugs (DMARDs) are the subject of several and often contraversal studies. In this review we present and analyzed the results of current research on the lipid profile in RA patients treated with the synthetic and biologic DMARDs. The role of the lipid profile alterations in the pathogenesis of accelerated atherosclerosis in RA has been discussed.
REFERENCES (61)
1.
Sihvonen S, Korpela M, Laippala P, et al. Death rates and causes of death in patients with rheumatoid arthritis: a population-based study. Scand J Rheumatol 2004; 33: 221-227. .
2.
Goodson N, Marks J, Lunt M, Symmons D. Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with oneself in the 1980s and 1990s. Ann Rheum Dis 2005; 64: 1595-1601. .
3.
Riise T, Jacobsen BK, Gran JT, et al. Total mortality is increased in rheumatoid arthritis. A 17-year prospective study. Clin Rheumatol 2001; 20: 123-127. .
4.
Thomas E, Symmons DP, Brewster DH, et al. National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year follow up study. J Rheumatol 2003; 30: 958-965. .
5.
Watson DJ, Rhodes T, Guess HA. All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol 2003; 30: 1196-1202. .
6.
Avińa-Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum (Arthritis Care Res) 2008; 59: 1690-1697. .
7.
del Rincón ID, Williams K, Stern MP, et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001; 44: 2737-2745. .
8.
Book C, Saxne T, Jacobsson LT. Prediction of mortality in rheumatoid arthritis based on disease activity markers. J Rheumatol 2005; 32: 430-434. .
9.
Kavanaugh A. Dyslipoproteinemia in subset of patients with rheumatoid arthritis. Ann Rheum Dis 1994; 53: 551-552. .
10.
Asanuma Y, Kawai S, Aoshima H, et al. Serum lipoprotein (a) and apolipoprotein (a) phenotypes in patients with rheumatoid arthritis. Arthritis Rheum 1999; 42: 443-447. .
11.
Lee YH, Choi SJ, Ji JD, et al. Lipoprotein (a) and lipids in relations to inflammation in rheumatoid arthritis. Clin Rheumatol 2000; 19: 324-325. .
12.
Solomon DA, Karlson EW, Rimm EB, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003; 107: 1303-1307. .
14.
Hahn BH1, Grossman J, Chen W, McMahon M. The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmunity 2007; 28: 69-75. .
15.
Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006; 6: 508-519. .
16.
Walldius G, Jungner I, Holme I, et al. High apolipoprotein B, low apolipoprotein A-1, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001; 358: 2026-2033. .
17.
Walldius G, Jungner I. The apo B/apo A ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy – a review of the evidence. J Intern Med 2006; 256: 493-519. .
18.
Sprecher DL, Watkins TR, Behar S, et al. Importance of high-density lipoprotein cholesterol and triglyceride levels in coronary heart disease. Ann J Cardiol 2003; 91: 575-580. .
19.
Duriez P, Fruchart JC. High-density lipoprotein subclasses and apolipoprotein A-1. Clin Chem Acta 1999; 286: 97-114. .
20.
Van Lenten BJ, Navab M, Shih D, et al. The role of high-density lipoproteins in oxidation and inflammation. Trends Cardiovasc Med 2001; 11: 155-161. .
21.
Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 2005; 96: 1221-1232. .
22.
Van Lenten BJ, Reddy ST, Navab M, Fogelman AM. Understending changes in high density lipoproteins during the acute phase response. Arterioscler Thromb Vasc Biol 2006; 26: 1687-1688. .
23.
Hahn BH, Grossman J, Ansell BJ, et al. Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 2008; 10: 213. .
24.
Mcmahon M. HDL as pro-inflammatory agent. Ann Rheum Dis 2013; (Suppl 3) OP 0005. .
25.
Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention the American Heart Association. Circulation 2003; 107: 499-511. .
27.
Dessein P, Joffe B, Singh S. Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthritis Res Ther 2005; 7: R634-R643. .
28.
Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP. The pathophysiologic roles interleukin-6 in human disease. Ann Intern Med 1998; 128: 127-137. .
29.
Gomaraschi M, Basilico N, Sisto F, et al. High-density lipoproteins attenuate interleukin-6 production in endothelial cells exposed to pro-inflammatory stimuli. Biochim Biophys Acta 2005; 1736: 136-143. .
30.
Feingold KR, Soned M, Staprans J, et al. Effect of tumor necrosis factor (TNF) on lipid metabolism in the diabetic rat. Evidence that inhibition of adipose tissue lipoprotein lipase activity is not required for TNF-induced hyperlipidemia. J Clin Invest 1989; 83: 1116-1121. .
31.
Kaplan MJ. Cardiovascular disease in rheumatoid arthritis. Curr Opin Rheumatol 2006; 18: 289-297. .
32.
Choi HK, Seeger JD. Lipid profiles among US elderly with untreated rheumatoid arthritis – the Third National Health and Nutrition Examination Survey. J Rheumatol 2005; 32: 2311-2316. .
33.
Dursunoglu D, Evrengul H, Polat B, et al. LP (a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation. Rheumatol Int 2005; 25: 241-245. .
34.
Georgiadis AN, Papavasilion EC, Lourida ES, et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment – a prospective, controlled study. Arthritis Res Ther 2006; 8: 82-88. .
35.
Park YB, Lee SK, Lee WK, et al. Lipid profiles in untreated patients with rheumatoid arthritis. J Rheumatol 1999; 26: 1701-1704. .
36.
Van Halm VP, Nielen MM, Nurmohamed MT, et al. Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann Rheum Dis 2007; 66: 184-188. .
37.
Munro R, Morrison E, Mc Donald AG, et al. Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis. Ann Rheum Dis 1997; 56: 374-377. .
38.
Banks M, Flint J, Bacon PA, et al. Rheumatoid arthritis is an independent risk factor for ischemic heart disease. Arthritis Rheum 2000; 43 (Suppl 1): 385. .
39.
Park YB, Choi HK, Kim MY, et al. Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. Am J Med 2002; 113: 188-193. .
40.
Choi HK, Hernan MA, Seeger JD, et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359: 1173-1177. .
41.
Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and the risk of hospitalization for congestive heart failure in rheumatoid arthritis. Rheumatology (Oxford) 2005; 44: 677-680. .
42.
Boers M. Rheumatoid arthritis: Treatment of early disease. Rheum Dis Clin North Am 2001; 27: 405-414. .
43.
Boers M, Nurmohamed MT, Doelman C J, et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis 2003; 62: 842-845. .
44.
Boers M, Dijkmans B, Gabriel S, et al. Making an impact on mortality in rheumatoid arthritis: targeting cardiovascular comorbidity. Arthritis Rheum 2004; 50: 1734-1739. .
45.
Suissa S, Bernatsky S, Hudson M. Antirheumatic drug use and the risk of acute myocardial infarction. Arthritis Rheum 2006; 55: 531-536. .
46.
Salomon DH, Avorn J, Katz JN, et al. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 3790-3798. .
47.
Davis III JM, Maradit Kremers H, Crowson CS, et al. Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population – based cohort study. Arthritis Rheum 2007; 56: 820-830. .
48.
Wolfe F, Michaud K. The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case- control analysis. Arthritis Rheum 2008; 58: 2612-2621. .
49.
Dahlqvist SR, Engstrand S, Berglin E, Johnson O. Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long- term infliximab therapy. Scand J Rheumatol 2006; 35: 107-111. .
50.
Popa C, Van Den Hoogen FHJ, Radstake TRDJ, et al. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann Rheum Dis 2007; 66: 1503-1507. .
51.
Seriolo B, Paolino S, Sulli A, et al. Effects of anti-TNF treatment on lipid profile in patients with active rheumatoid arthritis. Ann NY Acad Sci 2006; 1069: 414-419. .
52.
Tam LS, Tomlinson B, Chu TT, et al. Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin Rheumatol 2007; 26: 1495-1498. .
53.
Soubrier M, Jouanel P, Mathieu S, et al. Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis. Joint Bone Spine 2008; 75: 22-24. .
54.
Musni EM, Hoar B, Calabrese LH. The effect of TNF alpha treatment on lipid profiles of patients with systemic rheumatic disease. Arthritis Rheum 2008 (Suppl 2): Abs 1045. .
55.
Pollono EN, Lopez-Olivo MA, Lopez JA, Suarez-Almazor ME. A systemic review of the effect of TNF- antagonists on lipid profiles in patients with rheumatoid arthritis. Clin Rheumatol 2010; 29: 947-955. .
56.
Nishimoto N, Yoshizaki K, Miyasaka N, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004; 50: 1761-1769. .
57.
Maini RN, Taylor PC, Szechiński J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006; 54: 2817-2829. .
58.
Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study) a double-blind, placebo-controlled, randomized trial. Lancet 2008; 371: 2817-2829. .
59.
Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007; 66: 1162-1167. .
60.
Genovese MC, Mekay J, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008; 58: 2968-2980. .
61.
Liao K P, Cai T, Gainer VS, et al. Lipid and lipoprotein levels and trend in rheumatoid arthritis compared to the general population. Arthritis Care Res (Hoboken) 2013; 65: 2046-2050.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
